News

News

Holy Stone Healthcare and Gongwin Biopharm signed the cooperation agreement for IBD98-M Phase II Clinical Trial in China

27, Nov 2020

Gongwin Biopharm Co., Ltd. (Gongwin Biopharm) is a fully owned subsidiary of Gongwin Biopharm Holdings, Co., Ltd. Cayman (Gongwin-KY; ticker: 6617). Gongwin Biopharm is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer drugs. With PTS (Para-toluenesulfonamide) as the active pharmaceutical ingredient, Gongwin Biopharm has successfully developed PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of a rare disease, PTS500 for the treatment of malignant pleural effusion, and drugs for animal use. The applications of “minimally-invasive targeted tumor ablation therapy” for the treatment of cancer stand at a niche and leading position globally. (more information on Gongwin Biopharm: https://tw.gongwinbiopharm.com/)

IBD98-M is a combination therapy drug developed with the Hyaluronan Drug Delivery (HDD) technology platform of Holy Stone Healthcare. IBD98-M is an anti-inflammatory drug for the treatment of ulcerative colitis, which is manufactured by a patented process of combining 5-aminosalicylic acid (5-ASA) and hyaluronic acid. The special pharmaceutical design allows the 5-ASA to release at the proximal end of the colon. Meanwhile, hyaluronic acid inhibits inflammation through CD44 related signal pathway, and the viscoelasticity of hyaluronic acid forms a soft barrier to protect the inflamed sites from the irritations of gut microbes and other external factors. IBM98-M also increases the local concentration and bioavailability of 5-ASA in the inflamed site of the colon and enhance the anti-inflammation effects.

In this agreement, Holy Stone Healthcare and Gongwin Biopharm will collaborate on conducting IBD98-M Phase II Clinical Trial in China. Both parties will invest funds and manpower in this case. The remarkable experience of Gongwin Biopharm in conducting clinical trials in China, as well as its vast networks will benefit the planning and conducting of future clinical trials. In addition, both parties will cultivate the licensing opportunities in the China market to create a new era and share the profits.

previous page